1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Cann American Corp.

Cann American Corp.

CNNA
Cann American Corp.US flagOther OTC
0.00
USD
+0.00
- -
737,842.00Market Cap
Cann American Corp.
CNNA
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
TTM
FRC
- -
- -
- -
- -
- -
- -
Revenue per Share
-3.01
-20.87
-3.83
-84.56
-684.54
-589.67
Basic EPS, GAAP
-1.75
-23.11
-2.9
-15.97
-26.92
-87.81
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-7.4
-28.5
-23.43
-109.83
-828.64
-865.5
Book Value per Share
-0.07
-0.43
-4.12
-25.61
-118.86
-45.77
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
-2
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
1
1
1
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Feb'12
May'13
Aug'13
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Feb'12
May'13
Aug'13
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-18.52%
Free Cash Flow
- -
- -
28.42%
Net Income, GAAP
- -
- -
516.87%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
-4.43
-3.54
-4.79
- -
-84.56
2012
-35.73
-91.72
-371.74
- -
-684.54
2013
-104.79
-128.69
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
Similar Companies
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
Body and Mind Inc. (BMMJ)
FDC Limited (FDC.BO)
Medicure Inc. (MCUJF)
RPG Life Sciences Limited (RPGLIFE.NS)
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
Business
Cann American Corp. (OTCMKTS: CNNA) operates as a development-stage healthcare company focused on advancing innovative therapies and solutions to make healthcare more affordable and accessible through cutting-edge technology and regenerative medicine. Founded in 2004 and headquartered in Orlando, Florida, the company serves as a parent entity empowering subsidiaries under the Prodigy Elite Group, including Prodigy Stem Cell for non-invasive regenerative treatments; Prodigy Health Plus for discounted health plans covering dental, vision, LASIK, diabetic care, prescriptions, pet care, wellness programs, and preventive services; Prodigy Health Rx for digital prescription subscriptions; Prodigy Weight Loss programs; Prodigy Marketing; and Prodigy Wellness Centers targeting health and wellness facilities nationwide, primarily in the United States with expansion plans. Core offerings encompass stem cell therapies, alternative therapeutics, healthcare discount memberships, and related medical services aimed at reducing costs and improving patient outcomes across consumer and institutional markets. Recent developments include the acquisition of Prodigy Stem Cell completed on March 1, 2023, to enter the stem cell sector projected to reach $30 billion by 2030; the opening of a 3,000 sq. ft. Prodigy Stem Cell satellite office in Orlando, Florida, to support regional growth in tourism and sports training areas; the official launch of Prodigy Health Plus discount plans; and ongoing preparations for uplisting to the SEC reporting tier alongside debt restructuring and pursuit of partnerships such as a new memorandum of understanding with a biopharmaceutical entity valued at approximately $12 billion.

Company News

APIChat

  • accesswire.com

    Cann American Corp. Provides Shareholder Update